EXPERT INTERVIEWCMEABO MOC
Achieving Vascular Integrity in Retinal Diseases
|Author(s)/Faculty: Arshad M. Khanani, MD, MA, FASRS; Caroline R. Baumal, MD, FASRS; Carl D. Regillo, MD, FACS|
|Release Date: 6/30/2022||Expiration Date: 6/29/2023|
|Credit Type: CME / CME with ABO Continuing Certification ||Number of Credits: 1.25|
|Content Type: Lecture||Provider: |
Treatment burden and suboptimal responses observed in patients receiving intravitreal anti-vascular endothelial growth factor (VEGF) therapies for the management of retinal and choroidal vascular diseases defines a need for the identification of alternative therapeutic molecular targets. One such target is the angiopoietin/Tie pathway. Under normal physiological conditions, the Ang/Tie pathway maintains vascular stability and homeostasis, but in retinal vascular diseases, it leads to the promotion of vascular instability. The FDA recently approved the first agent that inhibits both the angiopoietin-2 (Ang-2) and VEGF-A pathways for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), providing the potential for enhanced visual acuity outcomes and extended dosing intervals when optimally integrated into clinical practice. In this continuing medical education activity, experts in the field review the role of the Ang/Tie pathway under physiological and pathological conditions and assess the safety and efficacy of therapeutic strategies that target the Ang/Tie pathway to improve outcomes in patients with retinal and choroidal vascular diseases.